 |
市場調查報告書
商品編碼
2076079
全球血漿蛋白治療市場：按產品類型、應用、最終用戶和地區分類Global Plasma Protein Therapeutic Market, By Product Type, By Application, By End User, By Geography |
||||||
全球血漿蛋白療法市場預計到 2026 年將達到 362.7 億美元，預計到 2033 年將達到 571 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 6.7%。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 362.7億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 6.70% | 2033年市場規模預測： | 571億美元 |
血漿蛋白療法是指源自人類血漿的治療產品，用於治療包括慢性病在內的多種疾病。血漿含有700多種不同的蛋白質，在體內發揮各種重要功能。主要的血漿蛋白療法包括免疫球蛋白、凝血因子、白蛋白和其他特殊蛋白質。這些血漿衍生產品有助於增強免疫系統、促進血液凝固並輔助其他代謝過程。隨著老年人口的增加以及慢性病患者數量的成長，全球對血漿衍生療法的需求也在增加。此外，先進的純化技術使得從血漿中以經濟高效的方式回收大量必需蛋白質成為可能。
市場動態：
全球血漿蛋白療法市場主要受免疫不全症和遺傳性疾病盛行率上升的驅動，這些疾病需要血漿替代療法。老年人口的成長，以及易患出血性疾病等慢性疾病的人群，也支撐了市場需求。持續的研發投入，致力於開發新的血漿衍生產品，以及醫療保險覆蓋範圍的擴大，都為該領域創造了機會。然而，嚴格的血漿採集監管以及血漿分餾設備所需的大量資本投資仍然是一個挑戰。此外，替代性重組療法的出現也對市場成長構成威脅。採購未經充分篩檢的血漿所帶來的安全隱患也阻礙了市場成長。
例如，根據美國國家生物技術資訊中心（NCBI）2023年6月26日發布的報告，2021年韓國原發性免疫力缺乏（PIDs）的發生率約為每百萬兒童11.25例。最常見的免疫力缺乏是抗體相關疾病，佔53.3%，其次是吞噬細胞疾病，佔28.9%。
本研究的主要特點：
- 本研究確定了各個細分市場的潛在收入成長機會，並為該市場說明了一個有吸引力的投資提案矩陣。
- 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
- 本研究根據以下參數介紹了全球血漿蛋白治療市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
- 這份《全球血漿蛋白治療市場》報告旨在為產業內的各類相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過分析全球血漿蛋白治療市場中使用的各種策略矩陣來簡化決策過程。
目錄
第1章：研究目標與前提條件
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 補體缺陷盛行率增加
- 高昂的研發成本與生產成本
- 免疫球蛋白用於治療各種疾病
- 影響分析
- 主要亮點
- 監管趨勢
- 服務提供組合
- PEST分析
- 波特的分析
- 併購情景
第4章 全球血漿蛋白治療市場：依產品類型分類，2021-2033年
- 白蛋白
- 免疫球蛋白
- 血漿衍生因子VIII
- 其他
第5章 全球血漿蛋白治療市場：依應用領域分類，2021-2033年
- 血友病
- 原發性免疫力缺乏（PIDD）
- 特發性血小板減少紫斑症（ITP）
- 其他
第6章 全球血漿蛋白治療市場：依最終使用者分類，2021-2033年
- 醫院
- 診所
- 研究所
- 其他
第7章 全球血漿蛋白治療市場：依地區分類，2021-2033年
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第8章 競爭情勢
- Octapharma USA Inc.
- Biotest AG
- Kedrion SpA
- CSL Limited
- Grifols, SA
- Takeda Pharmaceutical Company Limited.
- Octapharma AG
- Bio Products Laboratory（BPL）
- Shire Plc
- Albumedix Ltd.
第9章
- 調查方法
- 關於本公司
Global Plasma Protein Therapeutic Market is estimated to be valued at USD 36.27 Bn in 2026 and is expected to reach USD 57.10 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 36.27 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.70% | 2033 Value Projection: | USD 57.10 Bn |
Plasma protein therapeutic refers to therapeutic products that are derived from human blood plasma and are used for treating various medical conditions such as chronic disease and others. Blood plasma contains over 700 different proteins and serves various important functions in the body. Some of the major plasma protein therapeutics include immunoglobulins, coagulation factors, albumin, and other specialty proteins. These plasma derived products help in boosting the immune system, blood clotting, and other metabolic processes. With the growing geriatric population suffering from chronic diseases, there has been a rise in the demand for plasma therapeutics globally. Also, advanced purification technology has enabled significant yield of critical proteins from plasma in a cost-effective manner.
Market Dynamics:
The global plasma protein therapeutic market is driven by the rising prevalence of immune deficiency diseases and genetic disorders requiring plasma replacement therapies. The growing geriatric population prone to chronic illnesses like bleeding disorders is also supporting the demand. Continuous R&D efforts to develop new plasma-derived products and wider coverage under medical insurance schemes are providing opportunities in this space. However, stringent regulations pertaining to plasma collection and high capital requirements for plasma fractionation plants act as challenges. Also, the emergence of alternative recombinant therapies threatens the market growth. Safety concerns around plasma sourcing if not properly screened also hinder the market growth.
For instance, on June 26, 2023, according to a report published by the National Center for Biotechnology Information, in 2021, in South Korea, the occurrence rate of primary immunodeficiencies (PID) stood at around 11.25 cases per million children. The most commonly identified immunodeficiencies were those related to antibodies, constituting 53.3%, with phagocytic disorders trailing at 28.9%.
Key features of the study:
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global plasma protein therapeutic market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Octapharma USA Inc., Biotest AG, Kedrion S.p.A, CSL Limited, Grifols, S.A, Takeda Pharmaceutical Company Limited., Octapharma AG, Bio Products Laboratory (BPL), Shire Plc, and Albumedix Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global plasma protein therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protein therapeutic market
Global Plasma Protein Therapeutic Market Detailed Segmentation:
- By Product Type (Revenue, USD Bn, 2021 - 2033)
- Albumin
- Immunoglobulin
- Plasma-derived Factor VIII
- Others
- By Application (Revenue, USD Bn, 2021 - 2033)
- Haemophilia
- Primary Immunodeficiency Disorder (PIDD)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Others
- By End User (Revenue, USD Bn, 2021 - 2033)
- Hospitals
- Clinics
- Research Laboratories
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Top Companies in the Global Plasma Protein Therapeutic Market:
- Octapharma USA Inc.
- Biotest AG
- Kedrion S.p.A
- CSL Limited
- Grifols, S.A
- Takeda Pharmaceutical Company Limited.
- Octapharma AG
- Bio Products Laboratory (BPL)
- Shire Plc
- Albumedix Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Plasma Protein Therapeutic Market, By Product Type
- Global Plasma Protein Therapeutic Market, By Application
- Global Plasma Protein Therapeutic Market, By End User
- Global Plasma Protein Therapeutic Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Prevalence of Complement Deficiency Diseases
- High R&D and Production Costs
- Immune Globulin for Various Disease Treatment
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Service offering Portfolio
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Plasma Protein Therapeutic Market, By Product Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Albumin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Immunoglobulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Plasma-derived Factor VIII
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Global Plasma Protein Therapeutic Market, By Application, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Haemophilia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Primary Immunodeficiency Disorder (PIDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
6. Global Plasma Protein Therapeutic Market, By End User, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Research Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
7. Global Plasma Protein Therapeutic Market, By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2022 - 2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033,(US$ Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Octapharma USA Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biotest AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Kedrion S.p.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CSL Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Grifols, S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Octapharma AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bio Products Laboratory (BPL)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Shire Plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Albumedix Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
9. Section
- Research Methodology
- About us
